Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Griffin, J. Shockcor (2004)
Metabolic profiles of cancer cellsNature Reviews Cancer, 4
Jin-lian Chen, Huirong Tang, Jun-Duo Hu, Jing Fan, Jing Hong, Jian-Zhong Gu (2010)
Metabolomics of gastric cancer metastasis detected by gas chromatography and mass spectrometry.World journal of gastroenterology, 16 46
Y. Tsutani, Kazuhiro Yoshida, Y. Sanada, Y. Wada, K. Konishi, M. Fukushima, M. Okada (2008)
Decreased orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line.Oncology reports, 20 6
M. Bayet-Robert, D. Loiseau, P. Rio, A. Demidem, C. Barthomeuf, G. Stepien, D. Morvan (2010)
Quantitative two‐dimensional HRMAS 1H‐NMR spectroscopy‐based metabolite profiling of human cancer cell lines and response to chemotherapyMagnetic Resonance in Medicine, 63
E. Cutsem, V. Moiseyenko, Sergei Tjulandin, A. Majlis, M. Constenla, C. Boni, Adriano Rodrigues, Miguel Fodor, Yee Chao, Edouard Voznyi, M. Risse, J. Ajani (2006)
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group
J. Phang, Wei Liu, O. Zabirnyk (2010)
Proline metabolism and microenvironmental stress.Annual review of nutrition, 30
C. Fox, P. Hammerman, C. Thompson (2005)
Fuel feeds function: energy metabolism and the T-cell responseNature Reviews Immunology, 5
A. Cascino, M. Muscaritoli, C. Cangiano, L. Conversano, A. Laviano, S. Ariemma, M. Meguid, F. Fanelli (1995)
Plasma amino acid imbalance in patients with lung and breast cancer.Anticancer research, 15 2
E. Cutsem, V. Moiseyenko, S. Tjulandin, A. Majlis, M. Constenla, C. Boni, Adriano Rodrigues, M. Fodor, Y. Chao, E. Voznyi, M. Risse, J. Ajani (2006)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 31
A. Jemal, R. Siegel, Elizabeth Ward, Taylor Murray, Jiaquan Xu, Carol Smigal, M. Thun (2006)
Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 56
Jui Pandhare, S. Cooper, J. Phang (2006)
Proline Oxidase, a Proapoptotic Gene, Is Induced by TroglitazoneJournal of Biological Chemistry, 281
(2010)
Quantitative twodimentional HRMAS 1 HNMR spectroscopybased metabolite profiling of human cancer cell lines and response to chemotherapy
(2010)
Bio chemical disorders induced by cytotoxic marine natural products in breast cancer cells as revealed by proton NMR spectroscopybased metabolomics
D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, A. Norman (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer.The New England journal of medicine, 358 1
(1999)
KEGG: Kyoto encyclopedia of genes and genomics
Rayane Mohamed, E. Varesio, Gordana Ivosev, L. Burton, R. Bonner, G. Hopfgartner (2009)
Comprehensive analytical strategy for biomarker identification based on liquid chromatography coupled to mass spectrometry and new candidate confirmation tools.Analytical chemistry, 81 18
N. Schauer, Yaniv Semel, U. Roessner, A. Gur, I. Balbo, F. Carrari, T. Pleban, Alicia Perez-Melis, Claudia Bruedigam, J. Kopka, L. Willmitzer, D. Zamir, A. Fernie (2006)
Comprehensive metabolic profiling and phenotyping of interspecific introgression lines for tomato improvementNature Biotechnology, 24
R. Plumb, J. Granger, C. Stumpf, I. Wilson, Julie Evans, E. Lenz (2003)
Metabonomic analysis of mouse urine by liquid-chromatography-time of flight mass spectrometry (LC-TOFMS): detection of strain, diurnal and gender differences.The Analyst, 128 7
W. Koizumi, H. Narahara, T. Hara, A. Takagane, T. Akiya, M. Takagi, K. Miyashita, T. Nishizaki, O. Kobayashi, W. Takiyama, Y. Toh, T. Nagaie, S. Takagi, Y. Yamamura, K. Yanaoka, H. Orita, M. Takeuchi (2008)
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.The Lancet. Oncology, 9 3
D. Morvan, A. Demidem (2007)
Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways.Cancer research, 67 5
Yongmin Liu, G. Borchert, S. Donald, B. Diwan, M. Anver, J. Phang (2009)
Proline oxidase functions as a mitochondrial tumor suppressor in human cancers.Cancer research, 69 16
(2006)
Proline oxidase , a proapoptotic gene , is induced by triglitazone : evidence for both peroxisomal proliferator - activated receptor gammadependent andindependent mechanisms
J. Phang (1985)
The regulatory functions of proline and pyrroline-5-carboxylic acid.Current topics in cellular regulation, 25
K. Opstad, B. Bell, J. Griffiths, F. Howe (2008)
An assessment of the effects of sample ischaemia and spinning time on the metabolic profile of brain tumour biopsy specimens as determined by high‐resolution magic angle spinning 1H NMRNMR in Biomedicine, 21
C. Dang, G. Semenza (1999)
Oncogenic alterations of metabolism.Trends in biochemical sciences, 24 2
(2006)
Cancer statistics CA Cancer J Clin
L. Sumner, P. Mendes, R. Dixon (2003)
Plant metabolomics: large-scale phytochemistry in the functional genomics era.Phytochemistry, 62 6
T. White, Navasona Krishnan, D. Becker, J. Tanner (2007)
Structure and Kinetics of Monofunctional Proline Dehydrogenase from Thermus thermophilus*Journal of Biological Chemistry, 282
H. Horai, Masanori Arita, S. Kanaya, Yoshito Nihei, Tasuku Ikeda, Kazuhiro Suwa, Y. Ojima, Kenichi Tanaka, Satoshi Tanaka, K. Aoshima, Y. Oda, Yuji Kakazu, M. Kusano, Takayuki Tohge, Fumio Matsuda, Y. Sawada, M. Hirai, H. Nakanishi, Kazutaka Ikeda, N. Akimoto, T. Maoka, Hiroki Takahashi, T. Ara, N. Sakurai, H. Suzuki, D. Shibata, S. Neumann, T. Iida, Kenichi Tanaka, K. Funatsu, Fumito Matsuura, T. Soga, R. Taguchi, K. Saito, T. Nishioka (2010)
MassBank: a public repository for sharing mass spectral data for life sciences.Journal of mass spectrometry : JMS, 45 7
M. Bayet-Robert, Suzanne Lim, C. Barthomeuf, D. Morvan (2010)
Biochemical disorders induced by cytotoxic marine natural products in breast cancer cells as revealed by proton NMR spectroscopy-based metabolomics.Biochemical pharmacology, 80 8
Y. Liu, G. Borchert, A. Surazynski, J. Phang (2008)
Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancersOncogene, 27
A. Hirayama, K. Kami, M. Sugimoto, M. Sugawara, N. Toki, Hiroko Onozuka, T. Kinoshitá, N. Saitō, A. Ochiai, M. Tomita, H. Esumi, T. Soga (2009)
Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry.Cancer research, 69 11
(2006)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325
Metabolomics has developed as an important new tool in cancer research. It is expected to lead to the discovery of biomarker candidates for cancer diagnosis and treatment. The current study aimed to perform a comprehensive metabolomic analysis of the intracellular dynamic responses of human gastric cancer cells to 5-fluorouracil (5-FU), referencing the mechanisms of drug action and drug resistance. Small metabolites in gastric cancer cells and 5-FU-resistant cells were measured by liquid chromatography-mass spectrometry. Candidates for drug targets were selected according to the presence or absence of resistance, before and after 5-FU treatment. In addition, the gene expression of each candidate was assessed by reverse transcription-polymerase chain reaction. The number of metabolites in cancer cells dramatically changed during short-term treatment with 5-FU. Particularly, proline was reduced to one-third of its original level and glutamate was increased by a factor of 3 after 3 h of treatment. The metabolic production of glutamate from proline proceeds by proline dehydrogenase (PRODH), producing superoxide. After 5-FU treatment, PRODH mRNA expression was upregulated 2-fold and production of superoxide was increased by a factor of 3. In 5-FU-resistant cells, proline and glutamate levels were less affected than in non-resistant cells, and PRODH mRNA expression and superoxide generation were not increased following treatment. In conclusion, the authors identified a candidate biomarker, PRODH, for drug effects using a metabolomic approach, a result that was confirmed by conventional methods. In the future, metabolomics will play an important role in the field of cancer research.
Oncology Reports – Spandidos Publications
Published: Mar 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.